Review of: "Tocilizumab Plus Corticosteroid in Elderly Patients Hospitalized With COVID-19 Pneumonia: A Retrospective Cohort Study"

John Jairo Araujo, MD, NBE, FSIAC, FSISIAC, FACC

1 Interamerican Society of Cardiology

Potential competing interests: No potential competing interests to declare.

Thanks to the researchers for the opportunity to allow me to read and comment on this research related to the administration of Tocilizumab prescribed with corticosteroids to treat COVID-19.

The research conducted in older adults describes and analyzes the use of Tocilizumab prescribed with corticosteroids to treat COVID-19.

This research has an adequate methodology and design.

In my opinion, the investigation tries to respond to immunomodulation therapy for inflammatory syndrome in adulthood population infected with COVID 19, but the literature has shown that this inflammatory syndrome is more frequent in young people and with cardiovascular or systemic comorbidities, not in older people.

However, the use of Tocilizumab is based on the theory of immunomodulation and usefulness in other cytokine release disorder diseases, Tocilizumab is a drug that is used for the treatment of adults and children 2 years of age or older with the syndrome. of severe cytokine release, the medicine may decrease your immune system's ability to fight infection.

The research does not show benefits in the results of mechanical ventilation and it could even be no benefit in the final result in the older adult population.